CurrentPremera BluecrossPolicy G2014

15.01.029 Vitamin B12 And Methylmalonic Acid Testing

Defines reimbursement coverage for serum total vitamin B12 testing and methylmalonic acid (MMA) testing, including clinical indications, frequency limits, excluded tests (homocysteine, holotranscobalamin), and guidance referencing professional society recommendations. This part is the first of two and includes policy description, indications, coding header, terminology, background, analytical validity, clinical utility, and guideline citations.

Policy Summary

PayerPremera Bluecross

Policy15.01.029 Vitamin B12 And Methylmalonic Acid Testing

Policy CodePolicy G2014

Change TypeNew policy addition

Effective DateFeb 6, 2026

Next Review Date

Key ActionDocument pregnancy status, relevant signs/risk factors and test rationale when ordering total vitamin B12 or MMA testing to support reimbursement.

SourceLink

POLICY UPDATE CHANGES

New policy added to Routine Test Management Policy section and approved 11/01/2025.

SeveralCovered Indications (categories listed)

3-monthRepeat testing interval for many indications

3Primary tests referenced

1New policy addition (approval date)

annualMetformin monitoring frequency

Coverage summary and scope

Ref policy G2014 approved as a new policy on 11/01/2025 and effective for dates of service on or after Feb 6, 2026 following 90‑day provider notification. The scope defines reimbursement coverage for serum total vitamin B12 (serum cobalamin) testing and methylmalonic acid (MMA) testing, including clinical indications, frequency limits, excluded tests (holotranscobalamin and homocysteine for confirmation), coding header, terminology, background, analytical validity, clinical utility, and guideline citations (this is part one of two).

Key thresholds & quick facts

Serum total B12 low cutoff<200 pg/mL

Policy effective date (coverage applies to dates of service)2026-02-06

Policy approval / new policy dateApproved 11/01/2025 (added to Routine Test Management)

Repeat testing interval (reimbursable situations)Once every 3 months

Metformin monitoring frequency (chronic use)Once per year

Newborn MMA cutoff (study cited)0.423 µM (specificity 0.90, sensitivity 0.91)

Medically reimbursable indications and testing criteria

Medically Reimbursable Indications

Total vitamin B12 (serum cobalamin) testing is reimbursable for any of the following situations:

ANY of the following

Individuals who are pregnant
Neuropsychiatric signs (examples listed)
- Areflexia
- Cognitive impairment (including dementia-like symptoms and acute psychosis)
- Gait abnormalities

Not reimbursable tests and exclusions

Clinical guidance, recommended workflows, and diagnostic approach

Vitamin B12 (cobalamin) is required for erythropoiesis, metabolic reactions, neurological function, and DNA synthesis; deficiency can cause hematologic and neuropsychiatric disorders that are often reversible with early diagnosis and treatment. MMA accumulates when B12 is unavailable and serves as an indicator of functional B12 deficiency; holotranscobalamin (holoTC) is the metabolically active fraction and an emerging marker. Prevalence varies by population (≈6% under age 60, ≈20% over 60 in US/UK; higher in some regions). Major risk factors include malabsorption (Crohn disease, ileal resection, tapeworm), decreased intrinsic factor (atrophic gastritis, pernicious anemia, post‑gastrectomy), genetic defects (transcobalamin II deficiency), inadequate intake (alcohol abuse, older adults, vegans, eating disorders), and prolonged medication use (H2 blockers, metformin, proton pump inhibitors). Clinical manifestations range from fatigue and glossitis to macrocytic anemia and progressive neurologic impairment (peripheral neuropathy, gait disturbance, loss of vibration/proprioception, cognitive changes); early detection and supplementation can prevent progression to irreversible neurologic damage. The background emphasizes the importance of targeted testing to identify treatable disease early while avoiding indiscriminate population screening.

Definitions (term = short definition)

holoTCHolotranscobalamin — the metabolically active fraction of B12

Relevant codes and testing nomenclature

Relevant CPT codes mentioned in coding headerCPT

82607	Cyanocobalamin (Vitamin B-12)
83090	Homocysteine
83921	Organic acid, single, quantitative

Referenced tests (laboratory studies discussed)mixed

total vitamin B12	serum cobalamin (discussed as initial test and primary screening measure)
holotranscobalamin	active B12 (metabolically active fraction; discussed as an emerging/alternative initial test)
methylmalonic acid (MMA)	plasma methylmalonic acid; metabolic marker useful for diagnosis and monitoring of functional B12 deficiency
total homocysteine	alternative metabolic marker if MMA is unavailable; less specific than MMA
folate	recommended to assess in the B12 diagnostic work-up as part of evaluation
iron studies	recommended to assess in the B12 diagnostic work-up as part of evaluation (eg, ferritin, TIBC)

Required documentation, billing rules, and provider impact

Documentation Required

Indication documentation for B12 testing

When ordering total serum vitamin B12, document pregnancy status, any relevant neuropsychiatric, cutaneous, gastrointestinal, or hematologic signs, current treatment status, or one or more listed risk factors (eg, malabsorption, decreased intrinsic factor, genetic defects, inadequate intake, prolonged medication use) to support medical necessity and reimbursement.

Billing Rule

Repeat testing frequency for serum vitamin B12

Reimbursable total vitamin B12 testing is limited to once every three months for the indicated clinical scenarios (cutaneous, gastrointestinal, hematologic signs; individuals undergoing treatment; and those with listed risk factors).

Evidence summary and analytical validity

Key evidence summarized: Analytical validity for serum total cobalamin <200 pg/mL reports high sensitivity (~95–97%) but uncertain/possibly limited specificity (often <80%) with multiple assay pitfalls (assay failure, liver/renal disease, pregnancy, haptocorrin issues) limiting reliability of total B12 alone. Elevated serum MMA shows high sensitivity (>95%) and greater specificity than homocysteine for detecting functional B12 deficiency, though renal insufficiency and congenital metabolic defects are important pitfalls; newborn MMA cutoffs (e.g., 0.423 µM) demonstrated good sensitivity/specificity in a cited study. Evidence on cognition (AAFP/HQO meta-analyses) indicates very low‑quality evidence linking B12 deficiency to dementia onset and moderate‑quality evidence that B12 treatment does not improve brain function in established cognitive decline. Guideline and consensus recommendations (ADA, Vitamin B12 Consensus Panel, NICE, ASMBS and others) support targeted testing: consider periodic B12 assessment in chronic metformin users (ADA Grade B; Consensus Panel/others suggest annual testing), use either total B12 or holotranscobalamin as initial tests (NICE), and use a metabolic marker (preferably MMA; or homocysteine if MMA unavailable) to clarify indeterminate results and to monitor treatment effectiveness. The BMJ commentary cautions that serum B12, homocysteine, and MMA are unreliable predictors of B12‑responsive neuropathy and recommends basing treatment frequency on clinical symptoms with regular symptom monitoring rather than biomarker normalization.

Quantitative evidence metrics

Sensitivity: serum total cobalamin <200 pg/mL~95–97% (specificity uncertain, possibly <80%)

Specificity issues: total cobalamin

Revision history and material changes

11/01/2025policy_approval

New policy added to Routine Test Management Policy section and approved; Total vitamin B12 (serum cobalamin) testing may be considered reimbursable for indications outlined when criteria are met.

02/06/2026effective_dateLatest

Policy effective for dates of service on or after Feb 6, 2026 following 90-day provider notification; marked as material change.

Policy Summary

PayerPremera Bluecross

Policy15.01.029 Vitamin B12 And Methylmalonic Acid Testing

Policy CodePolicy G2014

Change TypeNew policy addition

Effective DateFeb 6, 2026

Next Review Date

Key ActionDocument pregnancy status, relevant signs/risk factors and test rationale when ordering total vitamin B12 or MMA testing to support reimbursement.

SourceLink

On This Page

Loss of proprioception and vibratory sense

Olfactory impairment

Peripheral neuropathy

title": "Medically Reimbursable Indications

ref_unused_dummy_field_to_meet_schema_fixup_1234

Reimbursable (repeat testing frequency) and Risk Factors

Total vitamin B12 (serum cobalamin) testing is reimbursable once every three months for any of the following situations:

ANY of the following

Cutaneous signs
- Hyperpigmentation
- Jaundice
- Vitiligo
Gastrointestinal sign: Individuals with gastrointestinal sign: Glossitis
Hematologic signs
- Anemia (macrocytic, megaloblastic)
- Leukopenia
- Pancytopenia
- Thrombocytopenia
- Thrombocytosis
Treatment monitoring: Individuals undergoing treatment for vitamin B12 deficiency
Risk factors
- Decreased ileal absorption
  - Crohn's disease
  - Ileal resection
  - Tapeworm infection
  - Prior or scheduled bariatric procedures (Roux-en-Y gastric bypass, sleeve gastrectomy, biliopancreatic diversion/duodenal switch)
- Decreased intrinsic factor
  - Atrophic gastritis

MMAMethylmalonic acid — indicator of functional B12 deficiency; metabolic marker

Total vitamin B12Serum cobalamin measurement used as an initial test for suspected B12 deficiency

Holotranscobalamin (active B12)Active B12 fraction — recommended alternative initial test to total B12

Total homocysteineAlternative metabolic marker when MMA is not available

Documentation Required

Use MMA as confirmatory test when appropriate

Use plasma methylmalonic acid (MMA) as a confirmatory test when appropriate (eg, asymptomatic high-risk individuals with low‑normal B12 or when deficiency is suspected despite normal/low‑normal serum B12). Document the clinical rationale for ordering MMA in these scenarios to justify reimbursement.

Documentation Required

Targeted testing rationale required

Per NICE, targeted testing requires documentation that the patient has BOTH at least one common symptom/sign of B12 deficiency AND at least one common risk factor; if relying on NICE criteria, record both the symptom(s) and the risk factor(s) when ordering testing.

Documentation Required

Assess additional markers and labs

As part of the diagnostic work-up for suspected B12 deficiency, assess additional markers and labs (MMA or total homocysteine as metabolic markers) and evaluate folate and iron status. If ordering advanced tests (eg, MMA), document the clinical justification for their use.

Prior Authorization

Policy implementation / reimbursement timing

This policy was approved 11/01/2025 as a new policy and is effective for dates of service on or after 2026-02-06 following a 90-day provider notification. Ensure dates of service meet the effective timing for coverage and reimbursement.

Denial Risk

Unnecessary testing risk

Avoid indiscriminate, population-wide screening of asymptomatic individuals. Routine testing without guideline-based symptoms or risk factors is not reimbursable and may be denied under routine test management.

Specificity uncertain; multiple pitfalls (assay failure, liver disease, renal disease, pregnancy, haptocorrin deficiency, folate deficiency, malignancy, HIV)

Sensitivity: elevated serum MMA>95% (specificity uncertain; renal insufficiency and congenital metabolic defects are pitfalls)

Newborn MMA cutoff (Rozmarič et al.)0.423 µM — sensitivity 0.91, specificity 0.90

Pregnancy trimester biomarker limits (study)Total B12 <89.9 & <84.0 pmol/L (1st & 2nd); holoTC <29.5 & <26.0 pmol/L; MMA >371 & >374 nmol/L

Postgastrectomy syndrome

Genetic: Transcobalamin II deficiency

Inadequate intake

Alcohol abuse
Individuals older than 75 years or elderly individuals being evaluated for dementia
Vegans or strict vegetarians (including exclusively breastfed infants of vegetarian/vegan mothers)
Eating disorder

Prolonged medication use

Histamine H2 blocker use for more than 12 months
Metformin use for more than four months
Proton pump inhibitor use for more than 12 months